BackDXP Enterprises Overview

DXP Enterprises Total Current Liabilities

DXP Enterprises's total current liabilities is $300M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$296.95M
20.98% YoYΔ $51.50M vs prior year quarter

Peer average / median

Loading

DXP Enterprises Total Current Liabilities History

Loading

DXP Enterprises vs. peers: Total Current Liabilities Comparison

Loading

DXP Enterprises Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

DXP Enterprises (DXPE) FAQ

DXP Enterprises posts a total current liabilities of $300M as of June 2026. That compares with $250M in the prior-year period — up 21.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, DXP Enterprises's total current liabilities was $250M. The latest reading is $300M — a 21.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of DXP Enterprises's financial statement story. At $300M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for DXPE's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; DXP Enterprises's other metric pages and overview cover the third.

Judging DXP Enterprises against Real Estate peers is usually better than using a market-wide rule of thumb. Business models inside Real Estate are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $300M here, then scan peer and history charts to see if the gap is persistent.